RADNOR, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is October 21, 2024. CONTA ...

SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024, inclusive (the “Class Period”), have until October 21, 2024 to seek appointment as lead plaintiff of the DexCom class action lawsuit. Captioned Alonzo v. DexCom, Inc., No. 24-cv-01485 (S.D. Cal.), the DexCom class action lawsuit charges DexCom as well as certain of DexCom’s top executives with violations of the Se ...

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, DexCom insiders caused the company to misrepresent or fail to disclose material information concerning expected revenue for the fiscal year 2024.   On July 25, 2024, Dexcom announced its financial results for the second quarter of fiscal ...

文章核心观点 - 公司DexCom开发用于糖尿病管理的葡萄糖监测系统 [2] - 公司曾表示有能力利用其增长潜力达到预期创纪录的新患者数量,同时超过上一财年的毛利率,并扩大客户向新G7平台的转换 [2] - 公司在2024年7月25日盘后公布了2024年第二季度的业绩不佳,并大幅下调了全年收入指引,导致股价大跌 [2] 公司概况 - DexCom是一家开发葡萄糖监测系统用于糖尿病管理的公司 [2] - 公司曾表示有能力利用其增长潜力达到预期创纪录的新患者数量,同时超过上一财年的毛利率,并扩大客户向新G7平台的转换 [2] 业绩表现 - 公司在2024年7月25日盘后公布了2024年第二季度的业绩不佳,收入指引从原先的43.5亿美元下调至40亿-40.5亿美元 [2] - 公司股价在2024年7月26日开盘时从107.85美元跌至66.60美元,下跌幅度达38% [2]

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=106365&from=3  CLASS PERIOD: January 8, 2024 to J ...

DexCom, Inc. (DXCM) is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust second-quarter 2024 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, risks related to stiff competition persist.This Zacks Rank #3 (Hold) company’s shares have lost 46.8% year to date against the industry’s 9.9% growth. The S&P 500 Index has increased 21.1% in the same time frame.DXCM, a renowned medical device company and provide ...

文章核心观点 - 血糖监测设备市场需求强劲,但DexCom并非唯一竞争对手 [1] - DexCom股价大跌的原因是公司下调了销售指引,第三季度销售增长预期仅1%-3% [2] - 竞争对手Abbott的FreeStyle Libre产品销售增长强劲,在同期超过DexCom的收入 [3] 根据相关目录分别进行总结 DexCom的市场机会 - DexCom的可服务市场巨大,仅美国就有2940万成人确诊糖尿病,另有870万未确诊 [4] - 预糖尿病人群也是DexCom的潜在客户,他们需要监测血糖应对疾病进展 [4] - DexCom还推出了面向非胰岛素使用人群的Stelo产品 [4] DexCom的风险因素 - 即使股价大跌,DexCom股票估值仍然较高,市盈率约39.8倍 [5] - 如果第三季度销售放缓趋势持续,股价还可能进一步下跌 [5] - 利利药物tirzepatide有望大幅降低糖尿病发病风险,可能缩小DexCom的市场 [6] - 美敦力推出新款可与Abbott CGM设备配合的胰岛素输注系统,将增强竞争力 [6][7]

文章核心观点 - 公司DexCom在2024年第二季度财报中下调了全年销售指引,原因包括新患者数量短缺、销售团队受到干扰以及G7产品的返利高于预期等 [2] - 公司股价在此消息公布后下跌超过40% [3] - 投资者指控公司在类期内做出了积极的声明,但同时隐瞒了销售团队无法执行公司增长计划的重要信息 [3] 根据相关目录分别进行总结 公司财务表现 - 公司下调了2024年全年销售指引,从之前的4.20-4.35亿美元下调至4-4.05亿美元,下调幅度约为3亿美元 [2] - 公司CEO表示公司的执行未达到高标准 [2] 公司运营情况 - 公司遭遇了新患者数量短缺7万人的情况 [2] - 公司销售团队受到了干扰 [2] - 公司在耐用医疗设备渠道的市场份额下降 [2] - G7产品的返利高于预期 [2] 股价表现 - 公司股价在消息公布后下跌超过40%,从84美元跌至64美元 [3]

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM), alleging that the medical device company made misleading statements about its financial performance and growth prospects. Hagens Berman urges DexCom investors who suffered substantial losses to submit your losses now. Class Period: Jan. 8, 2024 – July 25, 2024Lead Plaintiff Deadline: Oct. 21, 2024Visit: www.hbsslaw.com/investor-fraud/DXCM Contact the Firm Now: DXCM@hbsslaw.com       ...